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Abstract
As genomic and exomic testing expands in both the research and clinical arenas, determining
whether, how, and which incidental findings to return to the ordering clinician and patient
becomes increasingly important. Although opinion is varied on what should be returned to
consenting patients or research participants, most experts agree that return of medically actionable
results should be considered. There is insufficient evidence to fully inform evidence-based clinical
practice guidelines regarding return of results from genome-scale sequencing, and thus generation
of such evidence is imperative, given the rapidity with which genome-scale diagnostic tests are
being incorporated into clinical care. We present an overview of the approaches to incidental
findings by members of the Clinical Sequencing Exploratory Research network, funded by the
National Human Genome Research Institute, to generate discussion of these approaches by the
clinical genomics community. We also report specific lists of “medically actionable” genes that
have been generated by a subset of investigators in order to explore what types of findings have
been included or excluded in various contexts. A discussion of the general principles regarding
reporting of novel variants, challenging cases (genes for which consensus was difficult to achieve
across Clinical Sequencing Exploratory Research network sites), solicitation of preferences from
participants regarding return of incidental findings, and the timing and context of return of
incidental findings are provided.
Keywords
actionability; actionable genes; clinical sequencing; genomic medicine; incidental findings
BACKGROUND
Massively parallel DNA-sequencing technologies have been widely adopted in research and
are increasingly being used in a clinical context.1 However, the vast scale of the human
genome poses considerable interpretative challenges and necessitates novel approaches to
analysis, patient education, and genetic counseling. Among the most pressing concerns is the
potential discovery of incidental findings (IFs) unrelated to the indication for obtaining the
genomic test, previously termed the “incidentalome.”2 The clinical significance of genomic
IFs varies, as with incidental radiographic findings that may range from a mild deviation that
is not commented upon by the radiologist, to a benign-appearing nodule that is commented
on but requires no further evaluation, to a large unexpected mass that requires clinical
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follow-up. Likewise, the types of genomic variants include a multitude of variants with little
or no clinical implications as well as rare variants causally related to specific Mendelian
disorders. Although testing of disease-specific gene panels may obviate the issue of IFs,
these testing panels are evolving to encompass large numbers of genes and may be replaced
by genome-scale tests—similar to the way that a broad chemistry panel is generally run,
even when only a sodium level is ordered. As genome-scale testing is expanding in the
clinical and research arenas, determining how and which IFs to return to the ordering
clinician and patient becomes urgent.
In theory, all results could be shared with patients or subjects, but this approach is fraught
with potential problems because of practical issues such as time constraints, lack of
physician understanding, and the currently incomplete understanding of the consequences of
most human variations. A central tension in the return of genomic IFs is between the ethical
principles of “duty to warn” and “do no harm” on the part of physicians and the various
choices of patients, some of whom wish to “know everything” in their genome and others
who will undoubtedly wish to exercise their preference “not to know” certain findings.
Complicating this landscape further is the difficulty of communicating to patients the vast
array of possible results before embarking on testing so that they can make adequately
informed decisions. Although opinion is varied on what should be returned to consenting
subjects or patients, most geneticists agree that return of medically actionable results should
be considered. However, a recent survey has found a significant degree of both consensus
and difference in preferences among medical geneticists regarding specific examples of
IFs.3
The Clinical Sequencing Exploratory Research (CSER) network includes a group of six U01
projects begun in 2011 and funded by the National Human Genome Research Institute and
the National Cancer Institute, in which the impact of genome-scale testing is being
examined in diverse clinical settings. These projects share a common goal of studying the
implementation of genomic medicine; many address the topic of IFs in different clinical
contexts and use distinct approaches to the analysis and reporting of these results. The
impact of the return of IFs is being studied, with consideration of bioethical, economic, and
patient-reported health and psychosocial outcomes. Examining and comparing the
procedures used for determining which results to return—and in some cases, the actual gene
lists arrived at by different members of the consortium—will be useful to the community
because they represent implementation in a variety of contexts and may serve as examples
of what “real-world” groups are doing as they tackle this complex issue.
To that end, we present an overview of the approaches to IFs from genome-scale sequencing
by members of the CSER network. Our goal is to generate discussion of these approaches by
the clinical genomics community and to explore the types of findings that might be included
or excluded in various contexts. It should be noted that whether a given finding is
considered “incidental” depends entirely on the clinical context, and that certain findings
considered “incidental” in one clinical setting (e.g., a child with hearing loss) could have
“diagnostic” significance in a different setting (e.g., an adult with colon cancer), and vice
versa. Although most, if not all, CSER projects are actively exploring participant and/or
provider preferences, we have not summarized those ongoing studies here.
We emphasize that the strategies and specific lists provided here should be seen only as
starting points that must evolve and that will benefit from feedback. The American College
of Medical Genetics and Genomics (ACMG) has recently published recommendations for
clinical laboratories regarding the management of genomic IFs,4 and the Evaluation of
Genomic Applications in Practice and Prevention Working Group has developed a
streamlined evidence-based method for use in the development of guidelines.5 Both of these
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statements acknowledge the limited knowledge base currently available to inform clinical
practice. The CSER projects are, by design, carrying out research at the edge of clinical
practice, and thus it is hoped that the results will lend insight into best practices for clinical
genome sequencing. It is to be expected that there will be areas of disagreement among
projects, and these challenging cases may help bring attention to salient features that define
actionability. By providing examples of processes and context-dependent outputs, it is hoped
that the CSER experience can benefit other groups that would like to implement similar
procedures for the return of IFs. Although the primary focus of this exercise is not on
patient/participant consent, the processes that are developed to guide return of results will
directly influence the process of patient education and informed decision making.
PROJECTS AND PROCESSES
The CSER consortium represents a diverse collection of projects investigating the
application of genome-scale sequencing in different clinical settings, including pediatric and
adult sub-specialties, germline diagnostic testing, tumor sequencing, and specialty and
primary care.
• The Baylor College of Medicine (BCM) Baylor Advancing Sequencing into
Childhood Cancer Care project aims to incorporate Clinical Laboratory
Improvement Amendments–certified tumor and blood exome sequencing into the
care of children with newly diagnosed solid tumors.
• The Brigham and Women’s Hospital/Harvard Medical School (BWH/HMS)
MedSeq Project is focused on the integration of whole-genome sequencing into the
practice of medicine in two distinct domains: participants with a known genetic
disease and generally healthy participants.
• The Children’s Hospital of Philadelphia (CHOP) PediSeq Project is investigating
the use of genome-scale sequencing in the pediatric setting, with a focus on four
heterogeneous pediatric disease cohorts (bilateral sensorineural hearing
impairment, intellectual disability, nuclear-encoded mitochondrial respiratory chain
disorders, and sudden cardiac arrest/death).
• The collaborative CanSeq project between the Dana-Farber Cancer Institute and the
Broad Institute (DFCI/Broad) is specifically geared toward adult patients with
advanced cancer, with the goal of improving cancer patient outcomes by
identifying biologically consequential somatic (tumor) alterations that can be
targeted by existing or emerging anti-cancer agents.
• The NCGENES (North Carolina clinical Genomic Evaluation by Next-generation
Exome Sequencing) project at the University of North Carolina at Chapel Hill
(UNC) investigates the use of exome sequencing in adults and children in four
broad patient groups: hereditary cancer susceptibility, cardiogenetic disorders,
neurogenetic disorders, and congenital malformations.
• The New EXome Technology in Medicine (NEXT Medicine) project at the
University of Washington (UW) is a randomized controlled trial of exome
sequencing in patients with colorectal cancer or polyposis for whom a genetic test
is ordered in the course of usual clinical care.
Each project has established processes for determining the types of IFs to report (Table 1
and Supplementary Data and Supplementary Tables S1–S5, online). Committees with highly
similar expertise are used for evaluating genes for return a priori (three projects) or on a
case-by-case basis (three projects). Each project is using a unique framework for organizing
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types of IFs and returning results that is specific to the goals and research questions being
addressed (Table 2 and Supplementary Data and Supplementary Tables S1–S5, online).
CHALLENGING CASES
To further illuminate some of the similarities and differences in the processes used by the
different study teams, we constructed a small number of “challenging cases” that depict
examples for which actionability was considered particularly difficult to determine (Table
3). These examples demonstrate cases for which consensus may be difficult to achieve and
highlight areas in which contextual factors (such as the age of the patient population) and the
underlying framework may influence decisions about clinical actionability.
• Pharmacogenomic variants, such as those in cytochrome P450 2C19, were for the
most part not deemed actionable because the chance that an individual will receive
a given drug is low and, importantly, after prescription of that agent, there is
typically a chance for a clinician to make a decision about whether
pharmacogenomic testing should be obtained. Moreover, although
pharmacogenomic testing may ultimately be incorporated routinely into patient
care, there is no consensus at present on the utility of most such information. On
the other hand, malignant hyperthermia due to RYR1 mutations, which confers a
high risk of morbidity with exposure to general anesthesia, was felt to be actionable
by many groups due to the substantial chance of an individual undergoing general
anesthesia; the incomplete penetrance of the condition, which could result in a
negative family history of disease despite the mutation being present (thus escaping
clinical detection); the lack of routine testing in current anesthesia practice; and the
effectiveness of alternative anesthetic choices.
• Neurofibromatosis type 1 (NF1) is usually clinically recognizable, but many
affected individuals escape clinical detection until the diagnosis is established in a
family member. Due to discrete and specific recommendations for follow-up of
individuals with NF1, some groups considered a pathogenic mutation in the NF1
gene to be an actionable IF, whereas other groups considered the recommended
surveillance to have limited evidence of clinical utility in an asymptomatic
individual.
• Familial Mediterranean fever often results in a long diagnostic odyssey with
significant morbidity. This, coupled with the availability of an effective
prophylactic treatment, led some groups to consider familial Mediterranean fever
an actionable IF. Other groups felt that familial Mediterranean fever was
sufficiently diagnosable by standard techniques upon presentation and thus the
incidental discovery of a pathogenic mutation was not considered sufficiently
actionable.
• The Factor V Leiden mutation results in an increased chance of deep venous
thrombosis and possible serious morbidity due to embolism, and the absolute risk
depends on whether the individual is heterozygous or homozygous. Current
practice recommendations discourage screening for Factor V Leiden in otherwise-
asymptomatic individuals.6 Researchers at all CSER sites felt that the increased
chance of deep venous thrombosis was not sufficiently high in the heterozygous
state to reach an actionable threshold, whereas researchers at most sites chose to
include homozygous Factor V Leiden mutations as an actionable finding.
• Hemochromatosis has been well studied for possible population screening, but this
has not been recommended due to low penetrance and the number of individuals
needed to test in order to prevent morbidity.7 However, as discussed by the
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Electronic Medical Records and Genomics (eMERGE) consortium,8 the threshold
for return of a known result differs from that needed to justify population
screening. Due primarily to the fact that hemochromatosis confers a modest risk of
a very serious outcome that is highly preventable through minor intervention,
members at all CSER sites considered a homozygous p.C282Y mutation in HFE to
be actionable. However, compound heterozygosity for the p.C282Y with another
mutation was considered less actionable due to the much lower penetrance.
• The presentation of Gaucher disease differs depending on the specific mutation,
and the less severe forms can often be diagnosed in adulthood. Treatment with
enzyme replacement therapy is expensive but can mitigate symptoms. Groups
differed on whether homozygous pathogenic mutations would be considered
actionable if detected in children versus adults. This difference may be due to a
lack of published data to support the benefit of enzyme replacement therapy in
adult patients with no prior diagnosis (despite anecdotal experiences with
improvement in symptomatic patients diagnosed in adulthood).
• A number of cancer predisposition genes are actionable due to the impact of
screening and prophylactic measures. However, certain susceptibility loci, such as
CHEK2, were controversial due to the modest level of increased relative risk of
cancer conferred by pathogenic variants and the lack of clinical guidelines
regarding management of carriers of these mutations.
• Maturity-onset diabetes of the young is caused by mutations in a number of genes.
Early detection could lead to prompt management and potential mitigation of
morbidity and thus members at most CSER sites considered pathogenic mutations
in HNF1A to be actionable. However, because maturity-onset diabetes of the young
typically does not present with acute ketoacidosis, as is frequently the presenting
symptom in type I diabetes, and routine medical care would be likely to identify
affected individuals, the urgency of reporting this finding might be reduced.
• Finally, pathogenic mutations in genes associated with long QT syndrome convey a
risk of sudden cardiac death that is potentially preventable, which suggests
actionability. However, due to extensive locus heterogeneity, a number of genes
have been associated with long QT syndrome only in rare cases; as a result, the
existing knowledge base regarding the phenotypic spectrum of these subtypes of
long QT syndrome (such as LQT13) is quite small, leading some groups to
question whether to act on IFs in these genes.
DISCUSSION
In the context of IFs, it is clear that the vast majority of the variants detected by genome-
scale sequencing will have no discernible clinical importance, and only a small number will
have demonstrated health or reproductive implications. The approaches to returning IFs that
are being explored by the CSER network should provide evidence and guidance on best
practices for the clinical application of genome-scale sequencing tests. Several sites (CHOP,
UNC, and UW) use a priori categorization of genes, using the concept of actionability in
order to facilitate informed consent, analysis, and return of results. DFCI/Broad has adopted
the list of genes recommended by the ACMG for return of IFs4 as a starting point for
filtering germ-line noncancer IFs, with each alteration being evaluated on a case-by-case
basis. BCM assesses IFs on a case-by-case basis within a general framework established by
the BCM Medical Genetics Laboratory. BWH/HMS is returning all potentially clinically
valid findings within predefined categories but does not use clinical actionability in making
such decisions. None of the sites currently include patient groups or the public in their
processes to determine medical actionability. In general, the determination of whether
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specific gene mutations are actionable requires relevant medical and/or scientific expertise.
Although most, if not all, CSER projects are actively exploring preferences of participants
and/or referring providers about the type of results to disclose and the timing and method of
such disclosure, we have not summarized those ongoing studies here.
Given the recent release of the recommendations by the ACMG for return of certain
medically actionable IFs from genomic tests in clinical laboratories,4 we compared the
approaches of the participating CSER groups regarding such findings. There are some
similarities and some differences between the recommendations of the ACMG and the
various choices of the CSER projects, particularly around the issues of providing
participants the opportunity to “opt out” of receiving a small list of medically actionable IFs
and how medically actionable adult-onset disorders should be returned to the clinicians of
pediatric participants.
Variants of uncertain significance
The vast majority of genomic variants (such as novel or rare missense variants) will be of
uncertain clinical significance. Because it is presumed that the participant has not been
selected for a phenotype relevant to an IF, the prior probability that a given variant of
uncertain significance (VUS) is actually a disease-causing one is extremely low. Moreover,
in a clinical setting, it is critical not to overwhelm patients or their clinicians with false-
positive or uninterpretable results, which are prone to misinterpretation. It has been
documented that patients with VUSs in BRCA1 or BRCA2 have had surgical intervention,
often despite low risk that the VUS was pathogenic, 9 raising concerns regarding the hazards
of incorrect interpretation of a VUS result by patients and/or clinicians. Even more benign
interventions, such as increased radiological surveillance, are complicated by false positives,
radiation exposure, and unnecessary follow-up studies, thus having the potential to cause
anxiety for patients and add further health-care costs. Therefore, most of the groups in the
CSER consortium have arrived at the conclusion that, in the case of IFs, only known
disease-causing mutations or novel protein-truncating mutations with likely pathological
effect should be returned. By contrast, the MedSeq Project seeks to capture participant and
physician responses to “high-grade” VUSs related to Mendelian cardiac conditions in order
to explore how physicians and participants cope with such uncertainty and the potential
impact to the health-care system.
It is recognized that sensitivity is lost by setting a high bar for reporting of variants as IFs.
However, maximizing specificity was felt by many groups to be critical in this endeavor.
This contrasts with how VUSs are handled in a diagnostic setting, where maximizing
sensitivity to a greater extent is desirable and VUSs in genes relevant to the presenting
diagnosis would be reported. Thus, all of the CSER sites are returning VUS results for genes
relevant to the clinical diagnosis of the participant being sequenced.
Context and timing of return of results
The CSER network groups are handling the context and timing of return of results
differently in accord with the diverse study designs. Genetic counselors and physicians are
both involved in the return of results to participants at BCM, CHOP, UNC, and UW. At
BWH/HMS and DFCI/Broad, the ordering physicians return results to participants. In the
case of BWH/HMS, this method of returning results is related to the study goals of
understanding how genetically sophisticated and genetically naive physicians manage
genomic information. The UNC, BCM, and DFCI/Broad studies return any actionable IFs at
the same time as the diagnostic results, whereas UW returns IFs at a separate visit from the
return of colorectal cancer or polyposis findings in order to allow the participant to better
process the complex genetic information at each visit. CHOP offers participants the
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opportunity to receive diagnostic results and IFs in a single visit or to have a follow-up visit.
There is considerable diversity among CSER sites regarding the subsequent return of other
non–medically actionable findings in a participant- and/ or physician-driven fashion. For
example, the UW project prioritizes in-person delivery of results, whereas the NCGENES
project is studying the return of non–medically actionable findings using categories and
modes of delivery that are calibrated based on the chance that such results could cause
psychosocial harm.
Right of refusal of medically actionable IFs
There exists a significant difference among the CSER sites regarding the ability of
participants to refuse medically actionable IFs. Three sites (BCM, BWH/HMS, and UNC)
do not offer the participant/family in the CSER protocol an opportunity to refuse medically
actionable IFs once they have enrolled. CHOP and DFCI/Broad elicit preferences regarding
categories of IFs that participants would like to receive but reserve the right to overrule a
participant’s refusal in the case of IFs that are ruled “immediately medically actionable.”
UW allows participants to refuse any type of IF and specifically offers participants the
opportunity to decline different types of results by category at the return of the colorectal
cancer or polyposis–related primary results and again just before return of the IFs. Ideally, in
this situation, the participant will make a consistent decision and the medical geneticist
returning the results will not receive the refused results from the laboratory; however, the
participant may change his or her mind, which would place the provider in the tenuous
position of not returning a result that has been provided by the laboratory.
Although members at some CSER sites believe that the return of these results is both
necessary to their study design and an ethical obligation, conversations among group
members do indicate substantial differences of opinion about the role of individual
participant preferences for return of medically actionable IFs. Some investigators prioritize
the participants’ autonomy in deciding what to receive and express concern that participants
may refuse a genomic test if they cannot refuse IFs. However, there are clearly ethical and
legal differences in the responsibilities of researchers toward research participants versus
those of clinicians toward patients. Because the CSER projects are exploring genome-scale
sequencing in a clinical context, each CSER site must face such choices about participant
preferences in a research setting while gathering evidence about various clinical practices
for return of IFs. Some investigators expressed concern about the difficulty of consenting,
tracking, and other logistics related to individual preferences. Further, there were concerns
over liability for failure to return medically actionable results, even if refused. Although
informatics systems can mask results that a participant does not want from human view,
there is disagreement regarding whether such a mask obviates the “duty to warn” if such an
IF exists.
Differences between adult and pediatric participants
When considering the return of IFs in the pediatric population, several issues are unique: the
possibility of identifying results that are not relevant to the participant’s health in childhood,
such as adult-onset disease or information about carrier status; the impact of adult-onset
disease findings on the parents of children being tested; and the complexity of informed
consent for minors. These issues can make it more difficult to balance the principles of
beneficence and nonmaleficence with the autonomy of the pediatric participant and the
family. In addition, despite the natural tendency to divide disorders into pediatric- onset and
adult-onset conditions, such distinctions are not always clear cut, and the typical age of
onset for any given disorder does not always match the legal definition of “child” or “adult.”
Thus, an attempt to take into account the typical ages of onset of various conditions may
greatly complicate efforts to categorize genes in an a priori fashion.
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Not surprisingly, CSER sites evaluating only pediatric participant populations sometimes
diverged from those CSER sites evaluating only adult participants with respect to return of
results. CSER sites enrolling only adults may elect not to return IFs related to pediatric-onset
disorders, even if medically actionable. Indeed, genomic IFs suggestive of a typically
childhoodonset disorder, when discovered in an asymptomatic adult, may represent
hypomorphic alleles that manifest at the very mild end of a phenotypic spectrum, in which
case actionability is arguably reduced. Conversely, genomic results predicting adultonset
conditions may be appropriate for return to children when actionability extends to
prevention of disease in family members. At the same time, the benefits of return of results
must be weighed against the child’s autonomy and the potential harm of the child having to
bear the consequences of this information.
BCM, CHOP, and UNC are the three CSER sites that include pediatric participants. Because
of the substantial risk that an unsuspecting parent might harbor the same medically
actionable finding (such as a hereditary cancer syndrome) and could potentially benefit from
available prophylaxis or surveillance, BCM and UNC plan to return medically actionable
IFs related to adult-onset conditions to the parents of pediatric participants. By contrast,
CHOP does not routinely provide adult-onset medically actionable IFs but will allow parents
and/or children to elect whether or not to receive them. Although CHOP investigators are
aware that adult-onset conditions might have relevance to parental health, they support the
family’s right “not to know” certain incidental information about their child and the family,
particularly given the limitations in current understanding of the pathogenicity and
penetrance of many mutations.
Conclusion
In summary, the CSER network is exploring the application of genome-scale sequencing
tests through a variety of approaches to gather evidence about which genomic variants to
return as IFs and under what conditions. Some CSER sites have adopted the concept of
medical actionability to guide these decisions; however, the definition of actionability
differs among groups. This diversity, although sometimes due to different study populations,
offers a valuable opportunity to study the utility of these approaches. Here, we have outlined
differences and similarities in approaches. CSER sites differ not only in the process of
selecting genes for return of IFs but also in many other ways: the handling of VUSs; the
timing, context, and training of the person returning the result; the ability of participants to
select which results they would like returned (or not returned); the return of “nonactionable”
variants; and study populations (particularly between pediatric and adult participants). The
current practices of these ongoing studies highlight issues that need to be considered when
offering sequencing. We anticipate that the aggregate experience of the CSER sites may
inform future recommendations or guidelines on the clinical implementation of genomic
testing.
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